NINGBO INNO PHARMCHEM CO.,LTD. is pleased to announce the availability of 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde, identified by CAS number 283173-84-2. This compound serves as a crucial intermediate in the synthesis of active pharmaceutical ingredients, playing a vital role in the production of important therapeutic agents.
This high-quality intermediate is characterized by its physical properties and stringent specifications. It appears as an off-white to white solid, indicating a high degree of purity visually. Analytical testing by High-Performance Liquid Chromatography (HPLC) confirms a purity level of ≥99.0%, a critical factor for its use in complex chemical syntheses where impurities can impact downstream reactions and final product quality. The molecular formula is C18H13FN2O2, with a molecular weight of 308.30600. The product exhibits a melting point of approximately 219ºC. These carefully controlled specifications underscore the consistent quality provided by NINGBO INNO PHARMCHEM CO.,LTD., ensuring reliability for demanding pharmaceutical applications.
The primary application of 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde is as a key building block in the synthesis of Rucaparib. Rucaparib is a potent PARP inhibitor, a class of drugs used in the treatment of certain types of cancer, including ovarian cancer. Its complex synthesis pathway relies on high-purity intermediates like this aldehyde to achieve the desired yield and purity of the final active pharmaceutical ingredient. Its use as an intermediate is therefore critical to establishing the correct molecular structure and functionality required for Rucaparib's therapeutic efficacy. Reliable supply of this precisely specified intermediate is essential for pharmaceutical companies developing and manufacturing this important oncology treatment, helping to ensure consistent drug production and quality.
NINGBO INNO PHARMCHEM CO.,LTD. provides 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde in standard 25 kg drums. Custom packaging solutions are also available to meet specific customer requirements. Proper storage is essential to maintain product integrity; it should be stored in a cool, well-ventilated area away from incompatible materials. It is important to note that the product will not be offered to countries where it is covered by valid patents.
As a dedicated manufacturer and supplier of fine chemicals and pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing high-quality products like 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde. We aim to support our clients' synthetic processes with reliable supply and competitive price. For those looking to buy or purchase this specific Rucaparib intermediate, our team is ready to provide detailed product information, quotations, and support for your sourcing needs. We ensure transparency and efficiency throughout the purchase process, offering a dependable source for this crucial chemical intermediate.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.